New class of therapeutics for diabetes, obesity, prediabetes & weight los...


Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

A completely safe, new class of therapeutics  for
diabetes, obesity, metabolic syndrome, NAFLD, and weight management.

Over 1 Billion people are affected by diabetes and obesity, globally.
The World Health Organization now call diabetes and obesity a global epidemic. Existing therapies have failed to contain the growth of these diseases.

90 Million Metformin prescriptions are written in the US annually.
Metformin is the only first-line treatment for diabetes, yet it is not well-tolerated by a large portion of diabetics, and essentially only delays the progression of diabetes.

Awards & Industry Recognition

2019, “Top 500 Deeptech Startup Worldwide”-  Hello Tomorrow Global Challenge.
2019, “Leading Innovator Metabolic Condition Therapeutics” Healthcare & Pharma. Awards
2019, Finalist, US China Innovation Alliance InnoStars Competition, Wuhan, China.

Bonn Macy,  Co-founder, Chief Executive Officer
Former management consultant with McKinsey & Co. and BoozAllen; 20 + years experience in strategy, corporate planning, finance, & economics; U.S. Presidential appointee, 1997 - 2001. Founder & Director for both Startup Santa Fe and Startup New Mexico. Technology commercialization & startup expertise. B.S. Columbia University; M.S. Columbia University; M.Sc. London School of Economics. Graduate studies at University of Stockholm, University of Vienna, and London Business School.

Stephen Pandol M.D., Co-founder, Chief Science Director
Prof. of Medicine, UCLA; Director, Basic and Translational Pancreas Research, Cedar-Sinai Medical Center; President of the American Pancreatic Association, 2013 - 2014; Chief Editor for Frontiers in Gastrointestinal Sciences, past Associate Editor for the American Journal of Physiology,  Author of over 200 publications, including The Exocrene Pancreas, and 5 patents. 

Janine Lehmann, Co-founder, Product Director
Co-founder and Art Director, Trend Magazine. Co-founder, H-Haus, sustainable, modern modular architecture. Startup experience & expertise in operations, advertising, marketing and design. B.A. Hunter College, City University of New York.

Pedro Tetteroo, Ph.D. Advisor.  
Former General Manager and VP, Centocor (Johnson & Johnson). Pedro was instrumental in transforming Centocor from a start-up biotech to a full commercial - FDA approved - production and supply organization, including acquisition by Johnson & Johnson. Brought blockbuster drug, Remicade, to market. Boards: Leiden Bio Science Park and Postdoc Career Development Initiative (NL).

Ravinder Abrol, Ph.D, Advisor.   
Faculty, California State Univ., formerly  Northridge, Cedars-Sinai Medical Center, Depts. Of Medicine and Biomedical Sciences; Caltech, Director of Biomacromolecular Simulations, Materials and Process Simulation Center. Editor, International Journal of Chemical Physics, and Journal of Biophysics; Associate Editor, Frontiers in Physiology. Expertise: Molecular & Receptor Pharmacology, Molecular Mechanisms of Pharmacological Action.

Hongxiang Hui, M.D., Ph.D., Advisor.   
Dr. Hui is an expert on metabolic diseases, oncology, and wellness. Director and Professor of International Metabolic Medicine Center at China Southern Medical University; research scientist at UCLA; Chief Science Officer for a Hong Kong public company.

Yuan-Ping Han, Ph.D, Advisor.  
Prof. of Biochemistry, Molecular and Cell Biology, Sichuan University, Chengdu, China; Visiting Faculty: Cedars-Sinai Medical Center. Formerly Faculty, USC Norris Comprehensive Cancer Center, South California Research Center for Alcoholic Liver and Pancreatic Diseases and USC Research Center for Liver Diseases, Keck School of Medicine at USC.

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.

Request Access


No updates yet.


No backers yet.

Quick Signup TBD

You must have an account to do this!

the platform

Copyright © 2019 All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.